Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-021-21825-w http://scihub22266oqcxt.onion/10.1038/s41467-021-21825-w 33750821!7943568!33750821     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2021 ; 12 (1): 1517 Nephropedia Template TP {{tp|p=33750821|t=2021. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2 |pdf=|usr=}}{{33750821}} gab.com Text Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2 JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33750821 #FOAvip Up to date, effective antivirals have not been widely available for treating COVID-19. In this study, we identify a dual-functional cross-linking peptide 8P9R which can inhibit the two entry pathways (endocytic pathway and TMPRSS2-mediated surface pathway) of SARS-CoV-2 in cells. The endosomal acidification inhibitors (8P9R and chloroquine) can synergistically enhance the activity of arbidol, a spike-ACE2 fusion inhibitor, against SARS-CoV-2 and SARS-CoV in cells. In vivo studies indicate that 8P9R or the combination of repurposed drugs (umifenovir also known as arbidol, chloroquine and camostat which is a TMPRSS2 inhibitor), simultaneously interfering with the two entry pathways of coronaviruses, can significantly suppress SARS-CoV-2 replication in hamsters and SARS-CoV in mice. Here, we use drug combination (arbidol, chloroquine, and camostat) and a dual-functional 8P9R to demonstrate that blocking the two entry pathways of coronavirus can be a promising and achievable approach for inhibiting SARS-CoV-2 replication in vivo. Cocktail therapy of these drug combinations should be considered in treatment trials for COVID-19. Twit Text FOAVip Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2 ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33750821 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33750821 #FOAvip English Wikipedia <ref>{{Cite pmid|33750821}}</ref> Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2 #MMPMID33750821 Zhao H; To KKW; Lam H; Zhou X; Chan JF; Peng Z; Lee ACY; Cai J; Chan WM; Ip JD; Chan CC; Yeung ML; Zhang AJ; Chu AWH; Jiang S; Yuen KY Nat Commun 2021[Mar]; 12 (1): 1517 PMID33750821show ga Up to date, effective antivirals have not been widely available for treating COVID-19. In this study, we identify a dual-functional cross-linking peptide 8P9R which can inhibit the two entry pathways (endocytic pathway and TMPRSS2-mediated surface pathway) of SARS-CoV-2 in cells. The endosomal acidification inhibitors (8P9R and chloroquine) can synergistically enhance the activity of arbidol, a spike-ACE2 fusion inhibitor, against SARS-CoV-2 and SARS-CoV in cells. In vivo studies indicate that 8P9R or the combination of repurposed drugs (umifenovir also known as arbidol, chloroquine and camostat which is a TMPRSS2 inhibitor), simultaneously interfering with the two entry pathways of coronaviruses, can significantly suppress SARS-CoV-2 replication in hamsters and SARS-CoV in mice. Here, we use drug combination (arbidol, chloroquine, and camostat) and a dual-functional 8P9R to demonstrate that blocking the two entry pathways of coronavirus can be a promising and achievable approach for inhibiting SARS-CoV-2 replication in vivo. Cocktail therapy of these drug combinations should be considered in treatment trials for COVID-19. |*COVID-19 Drug Treatment[MESH] |*Drug Repositioning[MESH] |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |COVID-19/virology[MESH] |Chlorocebus aethiops[MESH] |Chloroquine/pharmacology[MESH] |Drug Discovery[MESH] |Female[MESH] |HEK293 Cells[MESH] |Humans[MESH] |Indoles/pharmacology[MESH] |Mice[MESH] |Mice, Inbred BALB C[MESH] |Peptides/*pharmacology[MESH] |SARS-CoV-2/*drug effects[MESH] |Serine Endopeptidases/metabolism[MESH] |Vero Cells[MESH]Cross-linking peptide and repurposed drugs inhibit both entry pathways(epmc).pdf DeepDyve Pubget Overpricing